Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Increase in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totaling 461,661 shares, a growth of 609.4% from the August 15th total of 65,075 shares. Based on an average daily trading volume, of 5,622,745 shares, the days-to-cover ratio is presently 0.1 days. Currently, 65.3% of the company’s stock are sold short.

Aethlon Medical Trading Down 1.9%

Shares of NASDAQ:AEMD opened at $1.53 on Friday. The firm has a market cap of $1.09 million, a PE ratio of -0.04 and a beta of 1.40. The company has a fifty day simple moving average of $2.79 and a 200 day simple moving average of $7.49. Aethlon Medical has a 12-month low of $1.52 and a 12-month high of $41.35.

Get Aethlon Medical alerts:

Aethlon Medical (NASDAQ:AEMD – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). As a group, equities research analysts forecast that Aethlon Medical will post -5.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AEMD has been the subject of several recent analyst reports. Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “neutral” rating and issued a $1.50 price target on shares of Aethlon Medical in a research note on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $1.50.

Read Our Latest Research Report on AEMD

Hedge Funds Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD – Free Report) in the third quarter, according to its most recent filing with the SEC. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

(Get Free Report)

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.

Featured Stories

• Five stocks we like better than Aethlon Medical
• Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
• Optical Cable Corporation Is Starting to Get the Market’s Attention
• Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
• Is Nike’s Index Demotion a Warning or a Buying Opportunity?

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.